This page is updated frequently with new Antibodies-related patent applications.
|| List of recent Antibodies-related patents
|Methods of diagnosis and treatment for pulmonary arterial hypertension|
Diagnostic and therapeutic agents for pulmonary arterial hypertension (pah) are provided. Circulating microparticles (mps) and/or the expression level of gpr75 are significantly increased in pah-pasmc, but not normal pasmc, thus, providing a non-invasive diagnostic method for pah.
The Regents Of The University Of California
|A diagnosing tuberculosis|
Mycolic acid antigen containing liposomes, and an electrode immobilised antigens of tuberculous mycobacterial origin are produced. A diagnostic sample from a human suspected of having tuberculosis is diluted and divided into first and second samples.
University Of Pretoria
|Monoclonal antibodies, hybridoma cell lines, methods and assays for detecting fungal phytase|
This invention relates to the field of immunology and more specifically relates to antiphytase monoclonal antibodies and immunoassay methods for the detection of a phytase from or derived from aspergillus niger (phya2) phytase, in particular, eh10a, fa7, af9a and cc1 antiphytase antibodies. The invention further relates to hybridoma cell lines that produce antiphytase monoclonal antibodies..
|Test st2 cardiac biomarker|
The technology described in this document can be embodied in a test strip for use in measuring a level of an st2 cardiac biomarker in a blood plasma sample. The test strip includes a base, and a plurality of conjugates, wherein each conjugate includes a reporter group bound to a first antibody that binds to st2.
Critical Care Diagnostics, Inc.
|Test st2 cardiac biomarker|
The technology described in this document can be embodied in a test strip for use in measuring a level of an st2 cardiac biomarker in a whole blood sample. The test strip includes a base, and a plurality of conjugates, wherein each conjugate includes a reporter group bound to a first antibody that binds to st2.
Critical Care Diagnostics, Inc.
|Prevention and treatment of pain using antibodies to lysophosphatidic acid|
Methods for preventing or treating pain are provided. Such methods comprise administering to a subject (e.g., a human subject) an antibody or antibody fragment that binds lpa.
|Anti-immunoglobulin e antibodies and methods of using thereof|
The present disclosure provides antibodies that specifically bind to circulating and receptor-bound ige and inhibit ige-mediated cell activation. The antibodies find use in various treatment, diagnostic, and monitoring applications, which are also provided..
|Human anti-sod1 antibodies|
Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or sod1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for sod1 are also disclosed.
University Of Zurich
|Medicament comprising anti-phospholipase d4 antibody|
The present application provides the medicaments comprising the antibodies binding to phospholipase d4 (pld4) as well as a method using said medicaments for detecting and suppressing activated b cells. The present application is further directed to therapy of auto-immune diseases and allergosis, resulting from the active-repressing function.
Sbi Biotech Co., Ltd.
|Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins|
This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., bont/a, bont/b, bont/e, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism..
The Regents Of The University Of California
Antibodies directed to her-3 and uses thereof
The present invention relates to binding proteins that bind to her-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided.
Antibodies to muc16 and methods of use thereof
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) muc16 ectodomain polypeptide, b) muc16 cytoplasmic domain polypeptide, and c) muc16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which muc16 is overexpressed, such as cancer..
Memorial Sloan Kettering Cancer Center
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
Anti-steap-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-steap-1 antibodies and immunoconjugates thereof are provided.
Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
The present invention relates to antagonists or inhibitors, which bind selectively to rankl/opgbp and regulate the interaction between rankl/opgbp and rank/opg. In particular, the present invention relates to an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a rankl/opgbppeptide for use in the treatment, prevention or alleviation of male infertility or reduced male fertility such as oligospermia or azospermia..
Rigshopitalet Copenhagen University Hospital
Antibodies for guanylyl cyclase receptors
Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.. .
Anti-fgfr3 antibodies and methods using same
The invention provides fgfr3 antibodies, and compositions comprising and methods of using these antibodies.. .
Human monoclonal antibodies to o8e
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to o8e with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E.r. Squibb & Sons, L.l.c.
Regulatory t cell mediator proteins and uses thereof
In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. Multiple sclerosis is disclosed.
Humanized or chimeric cd3 antibodies
The present invention relates to humanized or chimeric antibodies binding cd3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment..
Method for treating tumors that possess the cck-c receptor with the 3b9.1 monoclonal antibody
Human pancreatic cancer cells possess a distinct plasma membrane cck receptor variant that can be differentiated from the classic cck-b receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer..
Trpm4 channel inhibitors for stroke treatment
The present invention relates to methods for treating ischemic stroke including extension of the therapeutic time window for reperfusion. More particularly, the invention relates to a method of treating stroke in a subject by inhibiting the transient receptor potential melastatin 4 (trpm4) channel.
Singapore Health Services Pte Ltd
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described..
Labrys Biologics, Inc.
Antagonists to il-6 to raise albumin and/or lower crp
The present invention is directed to therapeutic methods using il-6 antagonists such as antibodies and fragments thereof having binding specificity for il-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum c-reactive protein level or a reduced serum albumin level prior to treatment.
Alderbio Holdings Llc
Anti-interleukin-33 antibodies and uses thereof
The invention provides interleukin-33 (il-33) antibodies and methods of using the same.. .
Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.. .
Humanized, anti-n2 antibodies and methods of treating ischemia-reperfusion injury
The present invention encompasses humanized antibodies that specifically bind n2 peptide, methods for the preparation thereof and methods for the use thereof.. .
Declmmune Therapeutics, Inc.
Anti-galectin-1 monoclonal antibodies and fragments thereof
The present invention is based, in part, on the discovery of anti-galectm-1 (gal 1.) monodonai antibodies useful for diagnostic and prognostic applications, as well as immunoglobulins, polypeptides, and nucleic acids thereof.. .
Dana-farber Cancer Institute, Inc.
Antibodies with ultralong complementarity determining regions
The present disclosure provides antibodies, including antibodies comprising ultralong cdr3 and uses thereof.. .
Anti-hemagglutinin antibodies and methods of use
The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.. .
Fine epitope peptide capable of inducing cross-reactive antibodies among homologous proteins in human papilloma virus e6 protein
This invention relates to the minimal motif of an epitope on the e6 protein from human papilloma virus (hpv), and this minimal motif of the epitope induces a monoclonal antibody having cross-reactivity with some homologous proteins of hpvs. The inventors are the first to identify a fine antigenic epitope only existing conservatively on the e6 proteins of high risk hpv16, 33, 52 or 58).
Guangzhou Hengsun Pharmaceutical Technology Co. Ltd.
Device with a lavet-type motor
In a device for ambulatory wearing by the patient containing a pump for delivery of injection fluid or for removal of analysis fluid, the drive motor for the mechanically driven pump system is a lavet-type stepper motor of small size designed for having a high mechanical power and low peak current requirement. Using this lavet-type motor for syringe-type or peristaltic preferably patch-type pumps high infusion rates needed for e.g.
Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
Disclosed are agents (e.g., peptides, polypeptides, proteins, small molecules, antibodies, and antibody fragments that target senescent cells) and methods of their use for imaging senescent cells in vivo and for treating or preventing cancer, age-related disease, tobacco-related disease, or other diseases and disorders related to or caused by cellular senescence in a mammal. The methods include administering one or more of the agents of the invention to a mammal, e.g., a human.
Unity Biotechnology, Inc.
Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Divalent vaccine compositions and the use thereof for treating tumors
The invention describes vaccine compositions combined in the same proportion with the extracellular domains of growth factor receptors her1 and her2 or fragments thereof and furthermore very small size proteoliposomes derived from proteins of the outer membrane of neisseria meningitidis and gm3 ganglioside (vssp-gm3), administered subcutaneously. The disclosed compositions, which induce the production of antibodies are used for the treatment of malignancies and offer advantages because they completely remove the tumor mass thus preventing tumor regression due to the emergence of resistant variants..
Centro De Inmunologia Molecular
Antibody-mediated anti-tumor activity induced by reishi mushroom polysaccharides
Immunogenic compositions, cancer vaccines and methods for treating cancer comprising fms, the fucose-enriched polysaccharide fraction from reishi f3, are provided. Compositions comprise fucose-enriched reishi polysaccharide fraction (fms) mw=˜35 kda, wherein the fms is isolated by size-exclusion chromatography from reishi f3, and the fms comprises polysaccharides having primarily a backbone selected from 1,4-mannan and 1,6-α-galactan, wherein the backbone is linked to a terminal fucose-containing side-chain immunogenic compositions comprising glycolipid adjuvants are provided.
Animal models and therapeutic molecules
The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited; The Bennet Building (b930)
Simultaneous assay of target and target-drug binding
Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding.
Laboratory Corporation Of America Holdings
Urine-based immuncassay for urocirtub 3 abd duagbisus if skeeo aobea
The present invention provides a method of identifying and isolating a set of monoclonal and polyclonal antibodies for use in immunometric assays for the detection of ucn iii peptide, and the development of a two-site immunoassay for ucn iii peptide. Monoclonal antibodies (mab) have been affinity purified and used to develop a two-site immunometric assay comprising a mab selected from the list comprising 2f7, 4e3, 4d3, 6d1, 1g10, 2e7, 4f3, 4c3, 5e11, 1a9, 4c4, 4b4, 2g7, 2a4, 1b9, 3h11, 5f2, 4g2, and 2e3 used for capture and a polyclonal antibody used for detection.
Methods of producing antibody-rich cannabis and honeysuckle plants
A method of producing antibody-rich cannabis and honeysuckle plants, and receiving the antibodies therefrom within a human body, is described. Antibody proteins are transfected or transduced to the dna of one or more cells of a cannabis or honeysuckle seed.
Thc Farmaceuticals, Inc.
Bispecific antibodies and methods for production thereof
The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an igg4-like ch3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an igg4-like ch3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfide-bond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention..
Humanized antibodies with ultralong complementary determining regions
The present disclosure provides humanized antibodies, including antibodies comprising an ultralong cdr3 and uses thereof.. .
Identification of vsig8 as the putative vista receptor (v-r) and use thereof to produce vista/vsig8 agonists and antagonists
The receptor for vista is identified (vsig8) as well as the use of this receptor in the identification or synthesis of agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of vsig8 and/or vista and/or the vsig8/vista binding interaction. These antagonists may be used to suppress vista's suppressive effects on t cell immunity, and more particularly used in the treatment of cancer, or infectious disease.
Anitbodies that bind urokinase plasminogen activator
The present invention relates to a method of identifying urokinase plasminogen activator (upa) antibodies. The invention also relates to antibodies that are capable of binding upa and which are capable of reducing or inhibiting u pa activity.
Novo Nordisk A/s
Antibodies to matrix metalloproteinase 9
The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), wherein the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.
Novel antibodies for the diagnosis and treatment of rheumatoid arthritis
Novel antibodies or binding fragments thereof, which exhibit specific binding to citrullinated epitopes are disclosed, as well as pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in diagnosis, in prognostics, treatment and/or alleviation of rheumatoid arthritis, as well as processes for generating and preparing said antibodies.. .
Antibodies with enhanced or suppressed effector function
Rationally designed antibodies and polypeptides that comprise multiple fc region amino acid substitutions that synergistically provide enhanced selectivity and binding affinity to a target fc receptor are provided. The polypeptides are mutated at multiple positions to make them more effective when incorporated in antibody therapeutics than those having wild-type fc components..
Antibody constant region variant
By means of amino acid sequence alterations, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production.
Chugai Seiyaku Kabushiki Kaisha
Binding molecules specific for her3 and uses thereof
The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the her3 receptor and inhibit various her3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life.
Combination therapy of anti-her3 antibodies
The present invention relates to the combination therapy of anti-her3 antibodies with certain anti-her antibodies.. .
Hoffmann-la Roche Inc.
Anti-b7-h4 antibodies and immunoconjugates
The invention provides anti-b7-h4 antibodies and immunoconjugates and methods of using the same.. .
Anti-cd79b antibodies and methods of use
The invention provides anti-cd79b antibodies and methods of using the same.. .
Anti-pd-1 antibodies and methods of use thereof
The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (pd-1) and methods of using same. The anti-pd-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases..
Rinat Neuroscience Corp.
Antibodies and methods of treating cancer
Described herein are antibodies against gpr49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against gpr49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of treating cancer with such antibodies..
Stabilized antibody compositions
The invention provides novel compositions of antibodies based on liquid vehicles selected from semifluorinated alkanes. The use of these vehicles provides for improved stability and shelf-life of antibodies and their derivatives.
Treatment of cancer with anti-il-1 alpha antibodies
Treating a patient with anti-il-1α antibody or anti-il-1α immunization s a cancer treatment.. .
Human fcrn-binding modified antibodies and methods of use
Herein is reported the use of an antibody comprising an fc-region with abolished fcrn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.. .
Hoffmann-la Roche Inc.
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to c5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, goodpasture's syndrome, and chronic obstructive pulmonary disease.. .
Alexion Pharmaceuticals, Inc.
Monoclonal antibodies against amyloid beta protein and uses thereof
The subject invention relates to monoclonal antibodies (e.g., 8f5 and 8c5) that may be used, for example, in the prevention, treatment and diagnosis of alzheimer's disease or other neurodegenerative disorders.. .
Abbvie Deutschland Gmbh & Co. Kg
Anti-s100a4 antibody molecules and their uses
Anti-s100a4 antibody molecules that are capable of inhibiting the biological activity of s100a4 in promoting tumour progression and/or in inducing tumour metastasis are described. The antibody molecules are also useful in the treatment of inflammatory conditions.
Cancer Research Technology Limited
Immunotherapy and diagnosis of mucormycosis using coth
The invention provided mucorales coth antibodies, polypeptides, encoding nucleic acid molecules, and uses thereof. The mucorales coth antibodies, polypeptides and encoding nucleic acids disclosed herein can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis..
Los Angeles Biomedical Research Institute Harbor-ucla Medical Center
Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
This application relates generally to the production of polypeptides having specific antigen-binding properties of fv domains, for example, insertable variable fragments of antibodies, and modified α1-α2 domains of nkg2d ligands.. .
Nogo receptor antagonists
Disclosed are immunogenic nogo receptor-1 polypeptides, nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are nogo receptor antagonist polynucleotides.
Biogen Ma Inc.
Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
Non-naturally occurring factor h binding proteins derived from variant 3 fhbp that can elicit antibodies that are bactericidal for at least one strain of n. Meningitidis, and methods of use of such proteins, are provided.
Children's Hospital & Research Center Oakland
Antibody targeting through a modular recognition domain
The present invention provides antibodies containing one or more modular recognition domains (mrds) for targeting the antibodies to specific sites. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also provided in the invention..
The Scripps Research Institute
Concentration and purification of hydrophobins and antibodies with a phase separation method
The present invention relates to a purification and concentration method for proteins and antibodies. Particularly the present invention relates to a continuous surfactant based phase separation method for recovering hydrophobin fusion proteins, and for recovering target molecules, such as antibodies, directly from a liquid by using phase separation and hydrophobin-protein a fusion technologies..
Teknologian Tutkimuskeskus Vtt Oy
Anti-claudin 1 antibodies for use in the treatment of colorectal cancer
The present invention relates to anti-claudin 1 antibodies for use in the treatment of colorectal cancer. In particular, the present invention relates to a method of treating a colorectal cancer in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an anti-claudin 1 (cldn1) antibody..
Institut RÉgional Du Cancer De Montpellier
Kits containing dll3 antibody drug conjugates
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. .
Antibodies for epidermal growth factor receptor 3 (her3)
This invention relates to antibodies or fragments thereof which interact with her family of receptors, e.g., her3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of her3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction.
Transgenic non-human mammal for producing chimeric human immunoglobulin e antibodies
The invention relates to a transgenic non-human mammal comprising human immunoglobulin mu and epsilon heavy-chain constant transgenes cμ and cε inserted in place of endogenous mu heavy-chain switch sequence sμ, and its use for producing chimeric human immunoglobulin e antibodies specific for an antigen of interest.. .
Université De Limoges
Microfluidic device to detect cannabis in body fluids
A microfluidic device for on-site quantitative detection of marijuana in body fluids has a body fluid collecting reservoir for receiving a body fluid and an anti-thc antibody reservoir that retains anti-thc antibodies. A first micromixer receives the body fluid from the body fluid collecting reservoir and the anti-thc antibodies from the anti-thc antibody reservoir to form a sample mixture.
Compositions and methods for the detection of anaplasma platys
Described herein are improved diagnostic tools for veterinary and human use which can be used for serodiagnosing a. Platys in mammals, particularly in members of the canidae family and in humans.
Ohio State Innovation Foundation
Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
The present invention relates to peptides biomarkers that are specifically recognized by autoantibodies present in the sera of patients with rheumatoid arthritis (ra). More specifically, the invention provides epitopes of pad4, of braf, and of calpastatin as well as methods and kits for using these sequences for the diagnosis of ra, in particular for the diagnosis of ra in ccp-negative subjects..
Universite De La Mediterranee - Aix-marseille 11
Device and rapid linker mediated label-based immunoassays
A method and system is provided which uses cleavable linkers to detect an analyte in an immunoassay. The use of linkers in elisa and similar immunoassay protocols allows for a reduction in wash steps, incubation time, and potential for user error.
Compositions and methods for binding lysophosphatidic acid
Compositions and methods for making and using anti-lpa agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against lpa are disclosed, as is a consensus anti-lpa monoclonal antibody variable domain sequence..
Treatment with anti-pcsk9 antibodies
The present invention concerns dosages for the treatment of human patients susceptible to or diagnosed with a disorder characterized by marked elevations of low density lipoprotein particles in the plasma with a pcsk9 antagonist antiboyd alone or in combination with a statin.. .
Antibodies directed to ricin toxin
An isolated monoclonal antibody or any antigen-binding fragment thereof which binds to ricin toxin, an expression vector including the isolated nucleic acid molecule and a host cell transfected with said isolated nucleic acid molecule or with the expression vector, a pharmaceutical composition including as an active ingredient the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule or the immunoconjugate and a pharmaceutically acceptable carrier, excipient or diluent, and a method of prophylaxis, treatment or amelioration of ricin toxin poisoning including administering to a subject in need thereof a therapeutically effective amount of the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule, the immunoconjugate or the pharmaceutical composition.. .
The Israel Institute Of Biological Research (iibr)
Antibodies that bind notum pectinacetylesterase
antibodies that neutralize notum pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting the bone.. .
Lexicon Pharmaceuticals, Inc.
Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
The present invention relates to an antibody that specifically binds to an epitope in the n-terminal part (residues 1 to 79) of tissue factor pathway inhibitor (tfpi). An antibody according to the invention may be capable of neutralising tfpi inhibition of the tf/fviia complex, even in the presence of elevated levels of tfpi.
Novo Nordisk A/s
Method for inhibiting cell growth using anti-erbb-3 antibodies
Methods for arresting or inhibiting cell growth, particularly cancer cell growth, comprising preventing or reducing erb-2/erbb-3 heterodimer formation, or interfering with erb-2/erbb-3 heterodimer conformation in a cell and agents which prevent or reduce erb-2/erbb-3 heterodimer formation or interface with erb-2/erbb-3 heterodimer conformation in a cell thereby arresting or inhibiting the growth of the cell.. .
Zensun (shanghai) Science & Technology Limited
Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide are disclosed. The antigen-binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, fab fragments, f(ab′)2 fragments, and single chain fv (scfv) fragments, as well as chimeric antigen receptors.
Memorial Sloan-kettering Cancer Center
Antibodies and chimeric antigen receptors specific for cd19
Provided are cd19 binding molecules, including anti-cd19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (cars). Among the antibodies are human antibodies, including those that compete for binding to cd19 with reference antibodies, such as murine antibodies.
Juno Therapeutics, Inc.
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
Methods for treating cancer in a patient in need thereof, with a therapeutically effective amount of an anti-4-1bb antibody in combination with a therapeutically effective amount of an adcc-inducing antibody, are disclosed.. .
Silent fc variants of anti-cd40 antibodies
The present invention relates to silent fc variants of anti-cd40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.. .
Methods for identifying immunobinders of cell-surface antigens
The invention provides methods for identifying immunobinders, such as scfv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods.. .
Esbatech, An Alcon Biomedical Research Unit Llc
Combination therapy for cancer
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (csf1r) in combination with pd-1/pd-l1 inhibitors are provided.. .
Bristol-myers Squibb Company
Antibodies to cd40
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to cd40, preferably human cd40, and that function as cd40 agonists. The invention also relates to human anti-cd40 antibodies and antigen-binding portions thereof.
Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
Methods of treating a subject having cancer exhibiting a resistance to a tyrosine kinase inhibitor (tki) are provided. Accordingly, there is provided a method comprising administering to the subject a therapeutically effective amount of antibodies comprising an anti-egfr antibody, an anti-her2 antibody and an anti-her3 antibody.
Yeda Research And Development Co. Ltd.
Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
In one embodiment, a masked monoclonal antibody (mab) is provided, the mab, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mab heterodimer complex is provided, comprising a first masked mab, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mab, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof..
Thomas Jefferson University
Antigen binding proteins capable of binding thymic stromal lymphopoietin
The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (tslp), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-tslp antibodies and derivatives of such antibodies.
Pan-elr+ cxc chemokine antibodies
antibodies are provided that specifically bind seven human elr+ cxc chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (ibd), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer..
Eli Lilly And Company
Anti-ngf antibodies and methods using same
The invention concerns anti-ngf antibodies (such as anti-ngf antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain..
Rinat Neuroscience Corp.
Antibodies to ß2-glycoprotein i and therapeutic uses thereof
Human recombinant antibodies or fragments thereof having specificity for the β2-glycoprotein i (β2gpi), pharmaceutical compositions containing same and use thereof in a method for treating or preventing thrombus formation and fetal loss in a patient affected by antiphospholipid syndrome (aps).. .
Methods and device to neutralize soluble toxic agents in the brain
Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include amyloid beta (aβ), and the methods, agents and devices are useful for reducing the accumulation of aβ, which is a principal constituent of the plaques associated with such diseases as alzheimer's disease (ad).
Antibodies against clostridium difficile toxins and uses thereof
antibodies that specifically bind to toxins of c. Difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein..
E. R. Squibb & Sons, L.l.c.
Anti-human papillomavirus 16 e6 t cell receptors
Disclosed is a t cell receptor (tcr) having antigenic specificity for an hla-a2-restricted epitope of human papillomavirus (hpv) 16 e6, e629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
Methods of delivering dll3 antibody drug conjugates
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. .
Monoclonal antibodies for ebola and marburg viruses
Described herein are a number of ebola monoclonal antibodies.. .
Her Majesty The Queen In The Right Of Canada As Represented By The Minister Of Health
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
The invention provides anti-igf-1r antibodies with abolished fcrn-binding and methods of using the same for the treatment of vascular eye diseases.. .
Hoffmann-la Roche Inc.
Leukolectins and uses thereof
The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal.. .